Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-5
SponsorMyo Munchee (Operations) Pty Ltd

About this trial

Multi-center, 6-month, randomized, and controlled trial to compare the effects of Myo Munchee therapy and Oral Motor Therapy (OMT) in pediatric patients (aged 3-5 years) to treat maxillary deficiency and orofacial myofunctional dysfunction (OMD).

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged between 36 - 60 (3-5 yrs) months old and will not turn 6 years of age before the study completion

Diagnosed with having at least two maxillary skeletal-dental malocclusion traits as determined by the dentist

At least one of the identified Orofacial Myofunctional Dysfunction (OMD) traits determined by the Speech-Language Pathologist (CCC-SLP)

Disqualifiers

A patient must be considered healthy to be included in this study. Definition of health: the patient does not have ongoing treatment, medication or specialized assessments (more than routine follow up exams) with health care providers regarding a condition. If they have had treatment for a condition (e.g. treated by respiratory physician for acute asthma hospitalization), it must have been 12 months or more since their last appointment with a health provider related to that condition.

Any previous or current tumors or traumas in the head, neck and jaw region Patients with any known genetic or congenital conditions that impair oral motor muscle function, oral motor coordination, or speech articulation, such as but not limited to muscular dystrophy, cerebral palsy, will be excluded from the study.

Patients with any known syndromic conditions to affect oral motor function, including but not limited to syndromes that involve craniofacial anomalies, neuromuscular disorders, or developmental delays affecting oral motor muscle control, speech articulation, or swallowing, such as Down Syndrome, Pierre Robin sequence, or Moebius syndrome.

Children that do not have their 2nd molars by 36 months of age

Trial design

Design model

Parallel

Treatments tested in this trial

  • Chewing device only

    Device

    This group will be administered the Myo Munchee and be given a protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.

  • Myo Munchee and Oral Motor Therapy Treatment

    Device

    This group will be administered an Oral Motoro Therapy program as well as a Myo Munchee protocol to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.

  • Oral Motor Therapy Treatment Arm

    Other intervention

    This group will be administered an Oral Motor Therapy program to follow over the 26-week study period. They will also have the clinical and questionnaire measurements taken at the beginning, week 10 and week 26 of the study.

Treatment groups

48 Participants
are divided into 4 treatment groups
Group A: Control groupNo intervention 0 interventions
Group B: Myo Munchee OnlyExperimental treatment 1 intervention
Group C: Oral Motor Therapy OnlyActive comparator 1 intervention
Group D: Myo Munchee and Oral Motor TherapyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Maxillary expansion

1. Palatal transverse width (in mm) expansion. Measured using an intraoral 3D iTero scanner. 2. Palatal sagittal depth (in mm) expansion. Measured using an intraoral 3D iTero scanner. 3. Palatal vault height (in mm) expansion. Intraoral measurements taken using an intraoral 3D iTero scanner, which is used to print a 3D model of the intraoral maxilla. The palatal height will then be measured using a GPM \& Holtain Palatometer (Model no. 215)

Time frame
26 weeks

Secondary outcomes

1

Resolution of dysfunctional resting mouth posture

Resting mouth posture outcome will be considered resolved if the below measurements are no longer present at the final evaluation. To assess this outcome, the Speech-Language Pathologist (SLP) will assess if: 1. Lips open when the child is resting 2. Mouth breathing during the day and night as mentioned by parent 3. Tongue rests on the floor of the mouth. The SLP will gently pull down the chin at rest and again look to see where the tongue is once the lips have opened. This is performed after movement, eating and while the patient is sitting. If any of these parameters is present at the first evaluation and then resolved at the final evaluation (i.e. no longer present), this will be consider a completed secondary outcome.

Time frame
26 weeks
2

Resolution of Oral Motor Development Sequence dysfunction

Oral Motor Development Sequence dysfunction will be determined by the SLP against 6 parameters, which is expected of a child to be able to do by 36 months of age: 1. Internal jaw stabilization 2. Tongue-tip elevation for swallowing 3. Appropriate jaw grading for biting and chewing 4. Gradual refinement of tongue movements 5. Circular rotary chew patterns 6. Mature swallow pattern The above criteria will be measured during the initial evaluation and determined if they have dysfunction in any of the domains (1-6). They will then be reassessed at 26 weeks during the final evaluation and assess if they have been resolved after completing the study's intervention.

Time frame
26 weeks
3

Improvement in patients sleep and behavior

Improvement in sleep and behavior as evaluated with the Children's General Airway Screening Protocol (C-GASP) Questionnaire.

Time frame
26 weeks
4

Improvement in patients sleep and behavior

Improvement in sleep and behavior as evaluated with the Sleep Disorders Inventory for Students-Revised (SDIS-R) by Child Uplift, Inc

Time frame
26 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.